UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

~~OR 15d-16~~ UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~April~~May 2025

Commission File Number: 001-36582

Altamira Therapeutics Ltd.

(~~Translation~~Exact name of registrant’s ~~name~~as ~~into~~specified in its ~~English~~charter)

Clarendon House, 2 Church Street

Hamilton HM 11, Bermuda

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number		Description
99.1		Press release, dated as of April 30, 2025

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Altamira Therapeutics Ltd. By: /s/ Thomas Meyer Name: Thomas Meyer Title: Chief Executive Officer

	Altamira Therapeutics Ltd.

Date: May 9, 2025	By:	/s/ Thomas Meyer
	Name:	Thomas Meyer
	Title:	Chief Executive Officer

~~Date: April 30, 2025~~1

EXHIBIT INDEX

Exhibit Number		Description
99.1		Notice to Shareholders dated May 9, 2025
99.2		Proxy Card for the Annual General Meeting of Shareholders
99.3		Notice of Internet Availability

Filing Compare · Altamira Therapeutics Ltd.